Dr M H Lessof (Guy's Hospital, London SEJ) Antilymphocytic Serumthe Possible Clinical Applications
The clearcut results obtained with antilymphocytic serum (ALS) in animals contrast with the inconclusive results obtained so far in man. Because of the toxicity of early ALS preparations, inadequate doses have been used in man and the choice of patients has often been limited to late and sometimes unsuitable cases. In renal transplantation, it is not ethical to omit conventional immunosuppressive treatment, since the beneficial effects of corticosteroids and azathioprine are considerable. In addition, combined immunosuppressive regimes may potentiate the effectiveness of ALS; however, they add considerably to the difficulty of analysing the results.
Intramuscular injections of horse globulin are painful in man. On the other hand, intravenous injections over a prolonged period may cause renal damage through the deposition of foreign globulin on the capillary basement membrane or by the deposition of immune complexes, which include horse antibody to human serum proteins and human antibody to horse globulin. The most recent preparations of ALS, notably those raised against thoracic duct lymphocytes, are more free of side-effects. They can cause a striking lymphopenia after an intravenous infusion, without causing pain, hmemolysis or a significant thrombocytopenia. Controlled clinical trials have thus become feasible, using standardized ALS of the type referred to by Dr Woiwod (p 949).
In reviewing the experimental situations in which ALS is effective, there is no doubt about its ability to prolong the survival of skin grafts in animals (Woodruff & Anderson 1963 , Levey & Medawar 1966 . Its use in homograft surgery in man is an obvious subject for further study. Animal experiments have also shown an effect upon other immune reactions which might have a clinical counterpart. Waksman et al. (1961) showed that ALS can prevent the allergic encephalomyelitis that follows an immunizing injection of brain emulsion. Currey & Ziff (1966) showed that it can prevent the arthritis which follows when rats are injected with Freund's adjuvant. Leibowitz et al. (1968) confirmed Waksman's findings in allergic encephalomyelitis and also found that ALS had a limited protective effect when its administration was delayed until the clinical features of encephalomyelitis appeared. The mechanism of this partial protection is still not clear and may represent a nonspecific antiinflammatory effect. Kalden et al. (1969) looked for an analogous situation in experimental allergic thyroiditis, which follows the injection of thyroglobulin. However, they could not demonstrate a protective effect when ALS is given after thyroglobulin has been injected into these animals. The potential usefulness of ALS in established immune disorders is therefore still a subject for investigation.
There are considerable difficulties over assessing any preparation of ALS for use in man, even when a standardized product is available. The rosette inhibition test (Bach et a. 1969) and the opsonization test (Greaves et al. 1969 ) are methods which are useful in vitro, but testing the effect on skin graft survival in primates has considerable advantages. In these in vitro tests it is possible to compare the toxicity as well as the effectiveness of different sera , Lance & Medawar 1970 .
Toxic effects in man can be reduced in various ways. Immune reactions to horse globulin can be prevented by pretreatment with aggregate-free normal horse globulin (Butler et al. 1969 , Brendel 1969 . Preliminary skin testing with horse globulin may also help to prevent anaphylactic reactions. The local pain of intramuscular ALS does not occur with intravenous injections and has not been a feature when goat ALS has been used (Pirofsky et al. 1969) . Fever is less prominent with the recently produced types of antilymphocyte globulin and it is also less marked when the globulin is given intravenously. However, some fever appears to be inevitable when a potent preparation is used, presumably because, like other cytotoxic drugs, ALS causes fever by liberating cell breakdown products. Hemolysis is prevented by absorption with red cell stroma. Thrombocytopenia and kidney damage have been less prominent since spleen has been out of favour for the raising of ALS. The risk of renal damage has also lessened with the increasing refinement and specificity of the newer sera. It may be a less prominent hazard if the duration of treatment is short. Short courses of treatment also help to lessen the risk of opportunistic infections and might be expected to lessen any chance of cancer supervening as a possible complication of immunosuppressive therapy.
Most clinical experience with ALS has been concerned with transplantation. Even without the benefit of controlled trials, the results in renal transplantation (Starzl & Porter 1968 , Doak et al. 1969 ) have been so good that a protective role of ALS seems quite possible in these cases. There have also been reports of dramatic improvement in extremely severe cases of dermatomyositis and temporal arteritis when ALS was added to the immunosuppressive regime (Trepel et al. 1968 ). Similar claims have been made in lupus nephritis and Goodpasture's syndrome (Pirofsky et a!.
1969).
The effectiveness and scope of ALS treatment in man remain to be assessed. It has the attraction of offering a relatively selective form of immunosuppressive therapy that suppresses cellular immunity without paralysing the antibody response to bacterial infection. Since 1958, when the human mitotic chromosome complement was first described paving the way to the detection of its abnormalities, some twenty (Polani 1970) more or less distinctive clinical syndromes have been identified, of which only two (Polani et al. 1954 , Plunkett & Barr 1956 , Polani et al. 1956 , Polani et al. 1958 ) had been accurately predicted with the backing of factual evidence, and one (Waardenburg 1932 , Bleyer 1934 had been presciently and shrewdly inferred (Waardenburg 1967) . Altogether, these syndromes and other less clearly clinically defined disorders account for abnormal foetal development in some 3j % of recognizable human pregnancies, and almost 90 % of the chromosomally abnormal conceptuses are eliminated as spontaneous abortions.
Broadly speaking, the main descriptive stage of human cytogenetics is in the phase of rapid deceleration, though one should stress that there are still many gaps in our knowledge of which I will instance only a few. For example: what is the actual relationship between criminal propensity and the 47,XYY state? Stated otherwise, what is the risk that the 47,XYY newborn, perhaps one in 500-700 of all newborn males (Ratcliffe et al. 1970) , faces in respect to psychosocial adjustment in our society? What happens to the numerous autosomal monosomic conceptuses that, in theory, should be complementary to the many who are trisomic? What estimates of risk can be given to balanced reciprocal translocation carriers? There is adequate knowledge about carriers of interchanges related to mongolism, and about the influence of the sex of the parent; but little is known about the other translocation types, yet interchanges affect perhaps one in 200-300 persons. What further contributions to human linkage studies can accrue from these and other cytogenetic studies? Some such questions await the result of further work, others of longitudinal studies, and yet others require even more careful probing among the early human reproductive failures or those in experimental or domestic animals.
At the present moment, much of the attention in human cytogenetics is directed at trying to understand the mechanism of origin of chromosome anomalies and their mode of action, namely the way in which a specific chromosome anomaly affects the phenotype. It is clear that the addition or subtraction of a whole chromosome, or visibly of even part of a chromosome, must upset gene balance by the addition or removal of possibly several hundreds of genes. The complexity of these genic factors must be kept in mind because while some will be of a structural variety, the blueprints for making polypeptides and enzyme proteins, others will have regulatory functions on structural genes, on blocks of genes or on chromosomes as a whole, their replication, their movement and division, or on cells, their division and mitotic cycle, &c. Yet others may be concerned with the production of special classes of gene products like transfer RNAs, the ribosomal RNAs, and perhaps some of the intranuclear RNAs concerned with control of other genes or parts of the genome, &c. The complexity of control in higher organisms is well realized and
